Bionote Inc. (377740) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bionote Inc. (377740:KRX), powered by AI.

Current Price
₩5,020
P/E Ratio
9.3
Market Cap
512.3B
Sector
Healthcare
What is the Bionote Inc. stock price forecast?

Bionote Inc. is currently trading at ₩5,020. View real-time AI analysis on Alpha Lenz.

What is Bionote Inc. insider trading activity?

View the latest insider trading data for Bionote Inc. on Alpha Lenz.

What is Bionote Inc.'s P/E ratio?

Bionote Inc.'s P/E ratio is 9.3.

Bionote Inc.

₩5.02K
KRX377740
Ask about Bionote Inc.'s future dividend policy...
Alpha Chat Insight

Bionote Inc. trades at a P/E of 9.3 (undervalued) with modest ROE of 3.5%.

Ask for details

Company Overview

Bionote Inc. is a leading biotechnology firm specializing in the research, development, and commercialization of diagnostic solutions. The company's primary mission is to enhance human and animal health through innovative diagnostic products that enable early and accurate detection of diseases. With a focus on both human and veterinary applications, Bionote Inc. develops advanced testing kits and instruments which are essential for clinical laboratories, medical institutions, and veterinary practices. Its diagnostic solutions cover a wide spectrum of conditions, making it pivotal in sectors such as medical research, healthcare services, and animal care industries. In the financial market, Bionote Inc. represents a vital player in the growing biotechnology industry, which is of increasing importance due to the rising emphasis on disease prevention and health management. Positioned at the forefront of the diagnostic field, Bionote Inc. contributes to the advancement of medical sciences and public health initiatives across the globe.

CEO조병기
SectorHealthcare
IndustryMedical Devices
Employees313

Company Statistics

(FY 2024)

Profile

Market Cap₩512.32B
Revenue₩102.78B
Shares Out102.06M
Employees313

Margins

Gross49.85%
EBITDA75.12%
Operating11.89%
Pre-Tax71.34%
Net53.77%

Valuation

P/E9.26
P/B0.31
EV/Sales4.98
EV/EBITDA5.29
P/FCF10.78

Growth (CAGR)

Rev 3Yr-45.14%
Rev 5Yr20.74%
Op Inc 3Yr-70.35%
Op Inc 5Yr4.24%
Net Inc 3Yr-56.61%
Net Inc 5Yr21.80%

Returns

ROA3.36%
ROE3.46%
ROIC4.47%

Financial Health

Cash & Cash Equivalents₩107.34B
Net Debt₩-45.96B
Debt/Equity3.75%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Bionote Inc. (Healthcare) Stock Forecast & Analysis ₩5,020 | Alpha Lenz